| Recruiting | KAN-004 for Immune-Related Diarrhea or Colitis NCT07196410 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 1 |
| Withdrawn | A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refr NCT05726396 | University of Minnesota | Phase 2 |
| Recruiting | Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis NCT07047339 | Changhai Hospital | Phase 2 / Phase 3 |
| Recruiting | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis NCT07012395 | Spyre Therapeutics, Inc. | Phase 2 |
| Enrolling By Invitation | Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology NCT06424769 | University of North Carolina, Chapel Hill | N/A |
| Recruiting | FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis NCT06206707 | University of Aarhus | N/A |
| Recruiting | Improved and Simplified Staining Technique for Dysplasia Detection in Colitis NCT06223347 | Vastra Gotaland Region | — |
| Recruiting | Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis NCT05947669 | Odense University Hospital | Phase 3 |
| Completed | Intestinal Biomarker Analysis After ECP for ICI Colitis NCT06074874 | University of Freiburg | — |
| Suspended | Optoacoustic Detection of Inflammation Using MSOT Device NCT05333978 | University of Oklahoma | N/A |
| Completed | ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment NCT05414552 | University of Freiburg | — |
| Unknown | Efficacy of a Low Fiber Diet for Pediatric Colonoscopy Prep NCT05918562 | Rhode Island Hospital | N/A |
| Recruiting | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer NCT03819296 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genito NCT04038619 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourina NCT04407247 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: NCT04272307 | University Hospital, Bordeaux | — |
| Completed | FIT and Fecal Calprotectin in Patients With Chronic Lower GI Symptoms NCT05514561 | Mahidol University | — |
| Unknown | Syndecan 1 as Biomarker for Inflammation NCT02333526 | Helios Albert-Schweitzer-Klinik Northeim | — |
| Completed | Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Dis NCT03601611 | Herlev Hospital | N/A |
| Completed | PediCRaFT: Pediatric Crohn's Disease Fecal Transplant Trial NCT03378167 | McMaster Children's Hospital | Phase 1 |
| Withdrawn | Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat Colitis NCT03014284 | The University of Texas Health Science Center at San Antonio | — |
| Completed | Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Co NCT02709213 | University Hospital, Geneva | — |
| Unknown | Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis NCT02687724 | University College Dublin | Phase 4 |
| Completed | Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis NCT02647866 | Kyowa Kirin, Inc. | Phase 2 |
| Withdrawn | Intestinal Microbiome and Chronic Inflammatory Bowel Disease NCT02768038 | Turku University Hospital | — |
| Completed | Patient Centered Algorithms to Optimize the Inpatient Experience and Treatment of Ulcerative Colitis NCT02569333 | Mount Sinai Hospital, Canada | N/A |
| Completed | Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort NCT02503514 | University of North Carolina, Chapel Hill | — |
| Completed | The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers NCT02063282 | Amos Yinnon | — |
| Completed | Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy. NCT02600143 | University Medical Center Groningen | — |
| Completed | A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to NCT01369355 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Se NCT01369342 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Croh NCT01369329 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel NCT01326013 | Luminex Molecular Diagnostics | — |
| Terminated | Intracolonic Vancomycin Therapy in Severe C. Diff Colitis NCT01346059 | Corewell Health East | N/A |
| Terminated | NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease NCT00936585 | National Institutes of Health Clinical Center (CC) | N/A |
| Completed | Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies NCT00533078 | Insel Gruppe AG, University Hospital Bern | Phase 2 |
| Withdrawn | Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome NCT00514982 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Evaluation of DHA for the Treatment of PSC NCT00325013 | Beth Israel Deaconess Medical Center | Phase 1 |
| Completed | Study to Identify Non-Invasive Markers of Gastrointestinal Allergy NCT00272818 | Boston Children's Hospital | — |
| Completed | Colonoscope Passive Bending Function NCT00518349 | Norwegian Department of Health and Social Affairs | N/A |
| Completed | A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease NCT00072943 | Facet Biotech | Phase 2 |
| Terminated | Treatment of Microscopic Colitis NCT00184171 | Norwegian University of Science and Technology | N/A |
| Completed | A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS NCT00002273 | Hoffmann-La Roche | N/A |
| Completed | A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovi NCT00000768 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |